Avalo Therapeutics FY2025 net loss widens 123% to USD 78 million, R&D expenses rise 105% to USD 50 million

Reuters03-23

Avalo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 net loss widens 123% to USD 78 million, R&D expenses rise 105% to USD 50 million

Avalo published a full-year earnings release reporting a net loss of USD 78.3 million and a loss from operations of USD 72.9 million.
Revenue was USD 59,000 and interest income, net was USD 4.4 million.
Research and development expenses rose more than doubled to USD 50.1 million, driven by costs supporting the Phase 2 LOTUS trial.
General and administrative expenses increased 33.1% to USD 22.9 million, primarily driven by stock-based compensation expense and headcount additions.
Cash, cash equivalents and short-term investments were USD 98.3 million, and Avalo said it expects this to fund operations into 2028; management also said topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) in hidradenitis suppurativa are expected in Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621777400?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621777400","market":"us","top_or_hot":-1,"title":"Avalo Therapeutics FY2025 net loss widens 123% to USD 78 million, R&D expenses rise 105% to USD 50 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 net loss widens 123% to USD 78 million, R&amp;D expenses rise 105% to USD 50 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Avalo published a full-year earnings release reporting a net loss of USD 78.3 million and a loss from operations of USD 72.9 million.\n        </li>\n<li>\n          Revenue was USD 59,000 and interest income, net was USD 4.4 million.\n        </li>\n<li>\n          Research and development expenses rose more than doubled to USD 50.1 million, driven by costs supporting the Phase 2 LOTUS trial.\n        </li>\n<li>\n          General and administrative expenses increased 33.1% to USD 22.9 million, primarily driven by stock-based compensation expense and headcount additions.\n        </li>\n<li>\n          Cash, cash equivalents and short-term investments were USD 98.3 million, and Avalo said it expects this to fund operations into 2028; management also said topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) in hidradenitis suppurativa are expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AVTX\">Avalo Therapeutics Inc</a>. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avalo Therapeutics FY2025 net loss widens 123% to USD 78 million, R&D expenses rise 105% to USD 50 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvalo Therapeutics FY2025 net loss widens 123% to USD 78 million, R&D expenses rise 105% to USD 50 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 net loss widens 123% to USD 78 million, R&amp;D expenses rise 105% to USD 50 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Avalo published a full-year earnings release reporting a net loss of USD 78.3 million and a loss from operations of USD 72.9 million.\n        </li>\n<li>\n          Revenue was USD 59,000 and interest income, net was USD 4.4 million.\n        </li>\n<li>\n          Research and development expenses rose more than doubled to USD 50.1 million, driven by costs supporting the Phase 2 LOTUS trial.\n        </li>\n<li>\n          General and administrative expenses increased 33.1% to USD 22.9 million, primarily driven by stock-based compensation expense and headcount additions.\n        </li>\n<li>\n          Cash, cash equivalents and short-term investments were USD 98.3 million, and Avalo said it expects this to fund operations into 2028; management also said topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) in hidradenitis suppurativa are expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AVTX\">Avalo Therapeutics Inc</a>. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLbHq2SV:1","article_id":"2621777400","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621777400","pubTimestamp":1774263696,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avalo published a full-year earnings release reporting a net loss of USD 78.3 million and a loss from operations of USD 72.9 million.Revenue was USD 59,000 and interest income, net was USD 4.4 million.Research and development expenses rose more than doubled to USD 50.1 million, driven by costs supporting the Phase 2 LOTUS trial.General and administrative expenses increased 33.1% to USD 22.9 million, primarily driven by stock-based compensation expense and headcount additions.Cash, cash equivalents and short-term investments were USD 98.3 million, and Avalo said it expects this to fund operations into 2028; management also said topline data from the Phase 2 LOTUS trial of abdakibart  in hidradenitis suppurativa are expected in Q2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AVTX":"Avalo Therapeutics Inc"},"translate_title":"Avalo Therapeutics 2025财年净亏损扩大123%至7800万美元，研发费用增长105%至5000万美元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVTX":0.9},"content_text":"Avalo Therapeutics FY2025 net loss widens 123% to USD 78 million, R&D expenses rise 105% to USD 50 million\n    \n\n\n          Avalo published a full-year earnings release reporting a net loss of USD 78.3 million and a loss from operations of USD 72.9 million.\n        \n\n          Revenue was USD 59,000 and interest income, net was USD 4.4 million.\n        \n\n          Research and development expenses rose more than doubled to USD 50.1 million, driven by costs supporting the Phase 2 LOTUS trial.\n        \n\n          General and administrative expenses increased 33.1% to USD 22.9 million, primarily driven by stock-based compensation expense and headcount additions.\n        \n\n          Cash, cash equivalents and short-term investments were USD 98.3 million, and Avalo said it expects this to fund operations into 2028; management also said topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) in hidradenitis suppurativa are expected in Q2 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621777400","isCrawlerRequest":true}